VTRS Q4 2021 Earnings — Viatris Inc. Revenue & Financial Results | Market Cap Arena

VTRSViatris Inc.

$17B

Q4 2021 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$4.3B+19.8% YoY

Gross Profit

$1.5B35.6% margin

Operating Income

-$78M-1.8% margin

Net Income

-$264M-6.1% margin

EPS (Diluted)

$-0.22

QoQ Revenue Growth

-4.3%

Cash Flow

Operating Cash Flow

$523M

Free Cash Flow

$302M

Stock-Based Comp.

$23M

Balance Sheet

Total Assets

$54.8B

Total Liabilities

$34.4B

Stockholders' Equity

$20.5B

Cash & Equivalents

$701M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4.3B	$3.6B	+19.8%
Gross Profit	$1.5B	$706M	+118.9%
Operating Income	-$78M	-$881M	+91.2%
Net Income	-$264M	-$916M	+71.2%

Revenue Segments

Brands

$2.6B60%

Generics

$1.4B32%

Complex GX and Biosimilars

$348M8%

Geographic Segments

Developed Markets Segment

$2.6B59%

Emerging Markets Segment

$728M17%

Japan, Australia and New Zealand Segment

$539M12%

Greater China Segment

$504M12%